Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.50 |
| ▸ | TUBB | P07437 | 2/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.50 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.50 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.50 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.50 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.50 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.50 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.50 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274675 | 0.89 | ALDH1A1 (0.81) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL6112770 | 0.89 | ALDH1A1 (0.81) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL611321 | 0.89 | ALDH1A1 (0.81) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL11627318 | 0.85 | ALDH1A1 (0.73) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL388362 | 0.81 | ALDH1A1 (0.69) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL31674038 | 0.81 | KDM4E (0.69) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL836908 | 0.81 | KDM4E (0.69) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL2591535 | 0.80 | KDM4E (0.66) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL25171514 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL3987174 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| EP-3880658-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113227055-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3680237-A1 | PROCESS FOR PREPARING SUBSTITUTED 2,3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | Arrien Pharmaceuticals LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2020-06-16 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| EP-0863136-A1 | Derivatives of azetidine and pyrrolidine | Akzo Nobel N.V. (NL) | 1998-09-09 | — | — | EP | disclosed |
| EP-0481705-A1 | Process for the preparation of arylalkylamines and substituted arylalkylamines | HOECHST CELANESE CORPORATION (US) | 1992-04-22 | — | — | EP | disclosed |
| US-5041669-A | Reacting alkyl aryl ketones with alkyl nitrites, extracting product, catalytically hydrogenating/reducing in nonaqueous acid mixture | HOECHST CELANESE CORPORATION (US) | 1991-08-20 | — | — | US | disclosed |
| US-4769368-A | DOPAMINE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0233049-A1 | 2,3,4,8,9,9a-Hexahydro-4-aryl-1H-indeno[1,7-cd]azepines | SMITHKLINE BECKMAN CORPORATION (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4505932-A | AMINOMETHYL-DIHYDROXY (DIALKOXY)-INDOLE, HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1985-03-19 | — | — | US | disclosed |
| US-4071562-A | 4,5-Dialkoxy-6 or 7-indanaldehydes | MARION LABORATORIES, INC. (US) | 1978-01-31 | — | — | US | disclosed |
| US-3963723-A | HYPOTENSIVE | MARION LABORATORIES, INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3962254-A | HYPOTENSIVE AGENTS | MARION LABORATORIES, INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3954774-A | HYPOTENSIVE AGENTS | MARION LABORATORIES, INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | RORA, RORB, RORC | KDM4E 2385/4885ALDH1A1 699/4885HPGD 1584/4885 |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | KDM4E 4478/4885ALDH1A1 2123/4885HPGD 1793/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | KDM4E 3495/4885ALDH1A1 2614/4885HPGD 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.